Correction: Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma

Goldberg JL, Navid F, Hank JA, *et al.* Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma. *J Immunotherapy Cancer* 2020;8:e000590. doi: 10.1136/jitc-2020-000590

Since the online publication of this article, the author names 'Jacquelyn A Hank' and 'Stephen D Gillies' were spelt incorrectly as 'Jacqueline A Hank' and 'Steven D Gillies'. This has now been corrected.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2020;8:e000590corr1. doi:10.1136/jitc-2020-000590corr1